Skip To Main Content
Jay S. Duker on Muck Rack

Jay S. Duker

As seen in: MDPI, Healio, Healio Ophthalmology, MarketScreener, Retinal Physician, touchOPHTHALMOLOGY, OCT News, Modern Retina
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jay S.

Contact Jay S., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Interpreting the LUGANO Trial

|
By Jay S. Duker, Jim Gallagher
| Retinal Physician Verified
Jay S. Duker, MD, discusses LUGANO’s missed primary endpoint, EyePoint’s ad hoc analysis of the data, and what the findings could mean for the ongoing phase 3 wet AMD program and Duravyu’s development in DME. On August 17, EyePoint, Inc. reported topline results from the phase 3 LUGANO trial of Duravyu (vorolanib intravitreal insert, or EYP-1901) for neovascular (wet) age-related macular degeneration (AMD).
Open in Who Shared Issue with article?

Phase 3 data support OTX-TKI’s durability in wet AMD: 1 injection, 1 year

|
By David Eichenbaum, Jay S. Duker, Ramiro Ribeiro
| Modern Retina
A novel intravitreal axitinib hydrogel demonstrated durable disease control in patients with treatment-naive neovascular age-related macular degeneration (AMD), with superior maintenance of visual acuity and anatomic outcomes compared with aflibercept 2 mg through 1 year. In a recent Ophthalmology Times® Rapid Readout, Arshad M.
Open in Who Shared Issue with article?

Viridian Therapeutics' Lumvoa receives FDA approval for thyroid eye disease across active and chronic stages

|
By David Eichenbaum, Jay S. Duker, Ramiro Ribeiro
| Modern Retina
Viridian Therapeutics has received FDA approval for veligrotug-vvze (Lumvoa) for the treatment of thyroid eye disease (TED), with labeling covering both active and chronic presentations regardless of disease activity or duration—a first among approved therapies in this class, according to the company.1 The biologics license application was designated Priority Review by the agency, and the company has indicated commercial availability will begin immediately.1 “The Lumvoa development program...
Open in Who Shared View Duplicates (3) Issue with article?
See all 36 articles